13.02.2024 PRESS RELEASE

Freiburg/Oxford: Alithea Bio is thrilled to announce a strategic collaboration with Exogene, co-funded by the German ZIM and Innovate UK, combining our expertise to spearhead #innovations in #T-cell receptor therapy, specifically for cancer treatment. 
  
With Alithea Bio’s focus on #massspectrometry analysis of #HLA-presented #peptides, Alithea Bio holds the largest database of HLA peptide mass spectrometric data, comprising 1.4 million unique peptides identified in 4.160 samples from healthy organs and tumors. In tandem with Exogene, we aim to expand this unique resource to identify novel #targets suitable for #TCR therapy. 
  
This collaboration seamlessly integrates Exogene‘s advanced AI-driven #T-cell receptor discovery methods with Alithea Bio‘s expertise in #HLA-peptidomics, streamlining the development of highly specific and effective #cancer therapies. Together, Alithea Bio and Exogene are poised to revolutionize cancer treatment, marking a significant leap forward in facilitating #safe and #effective #Tcell #receptor therapy.